WuXi AppTec has made significant strides in streamlining its operations and manufacturing processes. The company's efforts have resulted in improved efficiency and productivity.
By implementing a modularized manufacturing approach, WuXi AppTec has been able to increase its production capacity and reduce lead times. This approach has also enabled the company to offer more flexible and customized services to its clients.
WuXi AppTec's focus on innovation has led to the development of cutting-edge technologies, such as its proprietary molecular biology platform. This platform has enabled the company to accelerate its research and development processes.
The company's commitment to quality has led to the implementation of robust quality control measures, ensuring that all products meet the highest standards.
For your interest: In a Life Insurance Contract an Insurance Company's Promise
Operations and Manufacturing
WuXi AppTec has a global network that includes 20 sites across the world, with major hubs in China, the United States, Germany, Switzerland, and Singapore.
The company's extensive network allows it to serve a diverse range of clients, including Chinese drugmakers like Jiangsu Hengrui, as well as American and European firms like GlaxoSmithKline, AstraZeneca, and Pfizer.
As of 2025, WuXi AppTec reported around 39,000 employees, demonstrating its significant scale and resources.
Pharmaceutical Manufacturing
WuXi Chemistry's small molecule contract services added 1,187 new molecules in 2024.
The company's Chemistry segment saw significant growth in its new modalities business for oligonucleotides and peptides, TIDES, with a 70% year-over-year revenue increase to 5.8bn yuan.
The total reactor volume for solid-phase peptide synthesis reached 41,000 litres by the end of 2024.
WuXi plans to top 100,000 litres by the end of 2025, a significant expansion of its capabilities.
The company opened a small molecule active pharmaceutical ingredient manufacturing site in Taixing, China, in 2024.
It also increased dose capacity in Couvet, Switzerland, in the same year.
WuXi is building a formulation development and manufacturing site in Middletown, Delaware, in the US, which is expected to open by the end of 2026.
A research and development and manufacturing site in Singapore is also in the works, with some operations expected to start in 2027.
Consider reading: Site Internet Commerce
Operations
WuXi AppTec has a global network of 20 sites, with major hubs in China, the United States, Germany, Switzerland, and Singapore.
The company employs around 39,000 people, making it a significant player in the industry.
WuXi AppTec's services include drug discovery, development, and manufacturing for small molecules, peptides, and more.
As of 2025, the company has around 6,000 customers, including big-name firms like Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca, and Pfizer.
Curious to learn more? Check out: Management by Wandering around
Frequently Asked Questions
How much does the CEO of WuXi AppTec make a year?
The CEO of WuXi AppTec, Li Ge, earned a pre-tax annual salary of CNY41.8 million (approximately USD5.8 million) in the previous year. This made him the highest-paid chairperson among China's A-share listed companies.
Are WuXi AppTec and WuXi Biologics the same company?
No, WuXi AppTec and WuXi Biologics are sister companies, not the same entity. They are related but distinct businesses within the WuXi AppTec group.
Featured Images: pexels.com
